<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04099745</url>
  </required_header>
  <id_info>
    <org_study_id>KY20190823-02</org_study_id>
    <nct_id>NCT04099745</nct_id>
  </id_info>
  <brief_title>Comparing the Accuracy of Different Blood Glucose Monitoring Systems (CGM and FGM)</brief_title>
  <official_title>Comparing the Accuracy of Different Blood Glucose Monitoring Systems (CGM and FGM) With Venous Blood Glucose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing First Hospital, Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing First Hospital, Nanjing Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the accuracy of different blood glucose monitoring systems (CGM and FGM) in&#xD;
      diabetic patients with insufficient islet function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the accuracy of different blood glucose monitoring systems (CGM and FGM) in&#xD;
      diabetic patients with insufficient islet function with Venous Blood Glucose (including FGM&#xD;
      early, middle and late, pre-and post-meal, high and low blood glucose).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">October 1, 2019</start_date>
  <completion_date type="Anticipated">February 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Accuracy of different blood glucose monitoring systems (CGM and FGM) with intravenous blood glucose level as the gold standard</measure>
    <time_frame>2 weeks</time_frame>
    <description>To compare the accuracy of different blood glucose monitoring systems (CGM and FGM) with intravenous blood glucose level as the gold standard in diabetic patients with insufficient islet function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>three-day blood glucose fluctuation of CGM</measure>
    <time_frame>3 DAYS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>forty-day blood glucose fluctuation of FGM</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>CGM（continuous glucose monitoring）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each diabetic patient received three CGM tests within 14 days of FGM monitoring, on days 1-3, 6-9 and 12-14, respectively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FGM（Flash glucose monitoring）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each diabetic patient received one FGM test for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CGM</intervention_name>
    <description>Continuous Glucose Monitoring System</description>
    <arm_group_label>CGM（continuous glucose monitoring）</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FGM</intervention_name>
    <description>Flash glucose monitoring System</description>
    <arm_group_label>FGM（Flash glucose monitoring）</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  volunteer to participate and be able to sign informed consent prior to the trial.&#xD;
&#xD;
          -  patients with type 2 diabetes or type 1 diabetes, aged 18-80 years old.&#xD;
&#xD;
          -  No acute complications such as diabetic ketoacidosis, diabetic hyperosmolar syndrome,&#xD;
             etc.&#xD;
&#xD;
          -  Subjects are able and willing to monitor peripheral blood sugar and regularity of diet&#xD;
             and exercise.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with insulin allergy.&#xD;
&#xD;
          -  Impaired liver and kidney function with ALT 2.5 times higher than the upper limit of&#xD;
             normal value; Serum creatinine was 1.3 times higher than the upper limit of normal.&#xD;
&#xD;
          -  Drug abuse and alcohol dependence in the past 5 years.&#xD;
&#xD;
          -  Systemic hormone therapy was used in the last three months.&#xD;
&#xD;
          -  Patients with poor compliance and irregular diet and exercise.&#xD;
&#xD;
          -  Patients with pregnancy, lactation or pregnancy intention.&#xD;
&#xD;
          -  Any other obvious conditions or associated diseases determined by the researcher: such&#xD;
             as severe cardiopulmonary diseases, endocrine diseases, neurological diseases, tumors&#xD;
             and other diseases, other pancreatic diseases, history of mental diseases.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 16, 2019</study_first_submitted>
  <study_first_submitted_qc>September 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2019</study_first_posted>
  <last_update_submitted>September 19, 2019</last_update_submitted>
  <last_update_submitted_qc>September 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FGM</keyword>
  <keyword>CGM</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

